Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 29, 2021 - Issue 1
Submit an article Journal homepage
460
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Letermovir for the Management of Cytomegalovirus-associated Uveitis

Edmund Tsui1 F.I. Proctor Foundation, University of California, San Francisco, California, USA;2 Department of Ophthalmology, University of California, San Francisco, California, USAORCID Iconhttps://orcid.org/0000-0001-7532-9191View further author information
, MDORCID Icon,
John A Gonzales1 F.I. Proctor Foundation, University of California, San Francisco, California, USA;2 Department of Ophthalmology, University of California, San Francisco, California, USAORCID Iconhttps://orcid.org/0000-0003-0558-9793View further author information
, MDORCID Icon,
Jessica G. Shantha3 Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia, USAView further author information
, MD,
Nisha Acharya1 F.I. Proctor Foundation, University of California, San Francisco, California, USA;2 Department of Ophthalmology, University of California, San Francisco, California, USAView further author information
, MD, MS &
Thuy Doan1 F.I. Proctor Foundation, University of California, San Francisco, California, USA;2 Department of Ophthalmology, University of California, San Francisco, California, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2733-8370View further author information
, MD, PhDORCID Icon
Pages 169-174 | Received 30 May 2019, Accepted 27 Aug 2019, Published online: 22 Oct 2019

REFERENCES

  • Joye A, Gonzales JA. Ocular manifestations of cytomegalovirus in immunocompetent hosts. Curr Opin Ophthalmol. 2018;29:535–542.
  • Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39(4):597–638. doi:10.2165/00003495-199039040-00008.
  • Zandi S, Bodaghi B, Garweg JG. Review for disease of the year: treatment of viral anterior Uveitis: a perspective. Ocul Immunol Inflamm. 2018;26(7):1135–1142. doi:10.1080/09273948.2018.1498109.
  • Letermovir package insert. US Food and Drug Adminstration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209939orig1s000,209940orig1s000lbl.pdf. Accessed April 14, 2019.
  • Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516. doi:10.1016/j.ajo.2005.03.057.
  • Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011;11(5):1079–1084. doi:10.1111/j.1600-6143.2011.03530.x.
  • Chong PP, Teiber D, Prokesch BC, et al. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation). Transpl Infect Dis. 2018;20(5):e12965. doi:10.1111/tid.12965.
  • Turner N, Strand A, Grewal DS, et al. Use of letermovir as salvage therapy for drug-resistant Cytomegalovirus retinitis. Antimicrob Agents Chemother. 2019;63(3). doi:10.1128/AAC.00779-19.
  • Chou S, Satterwhite LE, Ercolani RJ. New locus of drug resistance in the human Cytomegalovirus UL56 gene revealed by in vitro exposure to letermovir and ganciclovir. Antimicrob Agents Chemother. 2018; 62(9): doi: 10.1128/AAC.00922-18.
  • Chou S. Rapid in vitro evolution of human Cytomegalovirus UL56 mutations that confer letermovir resistance. Antimicrob Agents Chemother. 2015;59(10):6588–6593. doi:10.1128/AAC.01623-15.
  • Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for Cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433–2444. doi:10.1056/NEJMoa1706640.
  • IBM. Micromedex RED BOOK.http://www.micromedexsolutions.com/. 2019.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.